AMGN ▼ -5.8% - Amgen Inc. $AMGN AMGN - IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER Amgen shares fell 5.8% despite announcing positive Phase 3 trial results showing that its combination therapy of Imdelltra and Imfinzi achieved a landmark improvement in overall survival for first-line extensive-stage small cell lung cancer. The decline suggests investors may have been expecting even stronger efficacy data, or the market is weighing the competitive and commercial challenges of bringing a combination therapy to a heavily contested oncology market. 08-SEP-2026 09:02 AM ET